Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22861414 | 0.81 | NPC1 (0.59) | NPC1HRH3KCNH2ALDH1A1USP2 | |
| SCHEMBL18713115 | 0.79 | NPC1 (0.67) | NPC1HRH3DRD3RAB9AALDH1A1 | |
| SCHEMBL23870336 | 0.79 | NPC1 (0.41) | NPC1HRH3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL28373903 | 0.77 | NPC1 (0.55) | NPC1HRH3KCNH2SIGMAR1 | |
| SCHEMBL25571582 | 0.77 | NPC1 (0.64) | NPC1HRH3KCNH2DRD3ALDH1A1 | |
| SCHEMBL2146652 | 0.77 | NPC1 (0.39) | NPC1HRH3DRD3RAB9AALDH1A1 | |
| SCHEMBL2146683 | 0.77 | NPC1 (0.39) | NPC1HRH3DRD3RAB9AALDH1A1 | |
| SCHEMBL13939521 | 0.75 | NPC1 (0.88) | NPC1HRH3KCNH2 | |
| SCHEMBL16016535 | 0.75 | NPC1 (0.88) | NPC1HRH3KCNH2 | |
| SCHEMBL13367 | 0.74 | NPC1 (0.66) | NPC1HRH3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210008041-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008041-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | NPC1 1541/4885HRH3 3363/4885HRH4 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.